Literature DB >> 15213561

Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs.

Antonio Pires1, Gareth Hardy, Brian Gazzard, Frances Gotch, Nesrina Imami.   

Abstract

To measure proviral HIV-1 DNA in patients treated with effective antiretroviral therapy (ART) during recent and chronic HIV-1 infection, and in long-term non-progressors (LTNP). We quantified HIV-1 DNA in peripheral blood samples from 39 HIV-1-infected subjects; 26 patients initiated non-nucleoside reverse transcriptase inhibitor (NNRTI) based ART at two different stages of infection: 16 during recent infection (RI) (HIV-1 exposure >60 days <1 year), and 10 during chronic infection (CI) (infected >2 years). The results were compared with those seen in 13 LTNP (infected >8 years, therapy naïve, and controlled viremia). Thirty-six weeks after initiation of ART, HIV-1-proviral DNA levels decreased from baseline in the RI group (P < 0.005) to levels comparable to LTNP. HIV-1 DNA also declined in the CI group (P = 0.053) but it remained significantly higher than in RI (P < 0.002) and LTNP (P < 0.02). However, plasma HIV-1 RNA levels become undetectable in 80% of CI patients 12 weeks post initiation of ART, compared to 41.2% in the RI group. All patients reached undetectable viremia by week 36 of therapy. These data indicate that initiation of NNRTI based ART during recent HIV-1 infection reduces HIV-1 DNA to levels comparable to those seen in LTNP, which is not apparent if therapy is started during chronic infection, and suggests an association between timing of initiation of ART and decay of the HIV-1 reservoir.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213561     DOI: 10.1097/00126334-200407010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

Review 1.  When to start antiretroviral therapy.

Authors:  Cunlin Wang; Saba W Masho; Daniel E Nixon
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

Review 2.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 3.  The detection and management of early HIV infection: a clinical and public health emergency.

Authors:  M Kumi Smith; Sarah E Rutstein; Kimberly A Powers; Sarah Fidler; William C Miller; Joseph J Eron; Myron S Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

4.  Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection.

Authors:  C T Burton; M R Nelson; P Hay; B G Gazzard; F M Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

5.  Short-course antiretroviral therapy in primary HIV infection.

Authors:  Sarah Fidler; Kholoud Porter; Fiona Ewings; John Frater; Gita Ramjee; David Cooper; Helen Rees; Martin Fisher; Mauro Schechter; Pontiano Kaleebu; Giuseppe Tambussi; Sabine Kinloch; Jose M Miro; Anthony Kelleher; Myra McClure; Steve Kaye; Michelle Gabriel; Rodney Phillips; Jonathan Weber; Abdel Babiker
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

Review 6.  Raltegravir in treatment naive patients.

Authors:  F Cossarini; A Castagna; Adriano Lazzarin
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

7.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

8.  Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.

Authors:  Anna A Herasimtschuk; Samantha J Westrop; Graeme J Moyle; Jocelyn S Downey; Nesrina Imami
Journal:  J Immune Based Ther Vaccines       Date:  2008-10-31

9.  Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.

Authors:  Samantha J Westrop; Nadeem A Qazi; Jeffrey Pido-Lopez; Mark R Nelson; Brian Gazzard; Frances M Gotch; Nesrina Imami
Journal:  PLoS One       Date:  2009-05-12       Impact factor: 3.240

10.  Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.

Authors:  Elizabeth Hamlyn; Fiona M Ewings; Kholoud Porter; David A Cooper; Giuseppe Tambussi; Mauro Schechter; Court Pedersen; Jason F Okulicz; Myra McClure; Abdel Babiker; Jonathan Weber; Sarah Fidler
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.